CollPlant (CLGN) VP details options and RSUs stake

Rhea-AI Filing Summary

CollPlant Biotechnologies Ltd VP Operations Oren Fahimipoor has reported his initial equity holdings in the company. He holds options to purchase 50,000 ordinary shares at an exercise price of $7.50 per share, expiring on March 28, 2033, with 34,375 options already vested and the remaining 15,625 vesting in five equal quarterly installments from March 28, 2026 through March 28, 2027, subject to continued service. He also holds 30,000 restricted share units, of which 13,125 are vested and 16,875 vest in nine equal quarterly installments from June 8, 2026 through June 8, 2028, also conditioned on continued service.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Fahimipoor Oren

(Last) (First) (Middle)

C/O COLLPLANT BIOTECHNOLOGIES LTD.

4 OPPENHEIMER ST, WEIZMANN SCIENCE PARK

(Street)

REHOVOT 7670104

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
CollPlant Biotechnologies Ltd [ CLGN ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP Operations

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Restricted Share Units(1)	30,000(2)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options to Purchase Ordinary Shares(1)(3)	03/28/2024	03/28/2033	Ordinary Shares	50,000(3)	$7.5	D

Explanation of Responses:

1. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee or director in connection with the Issuer's Share Ownership and Option Plan (2010) or 2024 Share Award Plan must be registered in the name of a trustee.

2. Of the restricted share units reported herein, 13,125 units are vested, and the remaining 16,875 units vest in nine equal quarterly installments beginning June 8, 2026 and ending June 8, 2028, subject to the Reporting Person's continued service to the Issuer as of such vesting date.

3. 34,375 options are fully vested and exercisable. The remaining 15,625 options shall vest and become exercisable in five equal quarterly installments beginning March 28, 2026 and ending March 28, 2027, subject to the Reporting Person's continued service to the Issuer as of such vesting date.

	/s/ Oren Fahimipoor	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What insider holdings does Oren Fahimipoor report in CollPlant (CLGN) Form 3?

Oren Fahimipoor reports equity-based compensation holdings in CollPlant. He holds options over 50,000 ordinary shares at $7.50 per share and 30,000 restricted share units, reflecting his position as VP Operations and aligning part of his compensation with company performance.

How many stock options does the CollPlant (CLGN) VP Operations hold and what are the key terms?

He holds options to purchase 50,000 ordinary shares at an exercise price of $7.50 per share. These options expire on March 28, 2033, with 34,375 already vested and 15,625 vesting in five equal quarterly installments from March 28, 2026 to March 28, 2027.

What are the vesting terms of the restricted share units reported by CollPlant (CLGN) VP Operations?

He holds 30,000 restricted share units, with 13,125 already vested. The remaining 16,875 RSUs vest in nine equal quarterly installments beginning June 8, 2026 and ending June 8, 2028, contingent on his continued service with CollPlant throughout the vesting period.

Does the CollPlant (CLGN) Form 3 indicate any recent insider buying or selling activity?

The Form 3 reflects initial beneficial ownership, not new market trades. It lists existing holdings of options and restricted share units for Oren Fahimipoor. The transaction summary shows no buy or sell transactions, only two holding entries with neutral net buy-sell direction.

How are CollPlant (CLGN) employee securities held for tax purposes under Israeli law?

The footnotes explain that, to qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities granted to employees or directors under CollPlant’s share plans must be registered in a trustee’s name, rather than directly in the individual’s name.